ViiV Healthcare announces positive result in TANGO Phase 3 study
Category: #health  By Paroma Bhattacharya  Date: 2019-07-11
  • share
  • Twitter
  • Facebook
  • LinkedIn

ViiV Healthcare announces positive result in TANGO Phase 3 study

ViiV Healthcare Limited, a pharmaceutical company specializing in HIV treatment, recently announced positive results from Phase 3 TANGO study.

The study was conducted to assess viral suppression in adults with HIV1 with a 2 drug regimen of dolutegravir in combination with lamivudine. Patients were chosen on the basis that they had previously maintained viral suppression for at least 6 months on a TAF (Tenofovir Alafenamide Fumarate) containing 3 drug regimens. It aimed to verify whether the same could be achieved through the 2 drug regimen. The results from the study will be presented at the 10th IAS Conference on HIV Science, in Mexico City.

Based on a proportion of participants with plasma HIV 1 RNA≥50 copies c/ml, using the Food & Drug Administration Snapshot algorithm at 48th week, the study has reportedly reached its primary end-point for non-inferiority. None of the patients developed treatment resistance in the dolutegravir and lamivudine arm of the study nor did they meet confirmed virologic withdrawal criteria. The safety results for the 2 drug regimen of dolutegravir in combination with lamivudine were consistent with the product labelling for the medicines.

Kimberly Smith, MD and Head of Global Research & Medical Strategy at ViiV Healthcare Limited, was reportedly quoted saying that the company has been developing the TANGO study to reduce the number of medicines in HIV treatment regimen to maintain viral suppression. The 48th week data from the final study proves that patients, who are already on treatment can maintain viral suppression if they switch from a 3 drug tenofovir alafenamide fumarate -containing regimen to a 2 drug regimen of dolutegravir in combination with lamivudine.

As per credible sources, the single-pill, 2-drug dolutegravir in combination with lamivudine, was authorized in U.S. earlier this year for the treatment of HIV-1 infection in adults with no ARV (antiretroviral) treatment history & with no known resistance to either lamivudine or dolutegravir. It was also authorized in Europe recently for the treatment of HIV 1 infection in adults & adolescents above 12 years, with minimum weight of 40 kg, with no known or suspected resistance to the INI (integrase inhibitor) class, or lamivudine.

Source credit: https://www.viivhealthcare.com/en-gb/media/press-releases/2019/july/viiv-healthcare-announces-phase-iii-study-meets-primary-endpoint/



About Author

Paroma Bhattacharya

Email: [email protected]   

Paroma Bhattacharya

Paroma currently works as a content developer for Algosonline, MSF and a series of alike platforms. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched ...

Read More

More News By Paroma Bhattacharya

Mirati Therapeutics reveals Phase ½ results of KRAS inhibitor therapy
Mirati Therapeutics reveals Phase ½ results of KRAS inhibitor therapy
By Paroma Bhattacharya

Mirati Therapeutics, an oncology company that engages in the development of targeted therapies, recently released its clinical trial results for MRTX849. Reportedly, MRTX849 is a KRAS G12C inhibitor and the data from P...

Best Buy to offer free next-day delivery feature on various products
Best Buy to offer free next-day delivery feature on various products
By Paroma Bhattacharya

Online retailers are always launching new and attractive deals during the holiday season, as it grosses the highest sale time for the year. Several retailer rollout out attractive offers, such as discounts or complimen...

Nature Tech Corp partners with Aldevron for gene therapy manufacturing
Nature Tech Corp partners with Aldevron for gene therapy manufacturing
By Paroma Bhattacharya

The global cell and gene therapy sector is expected to witness a thriving period of growth over the forthcoming years. In fact, owing to the favorable growth conditions across the industry, numerous biotechnology and p...